ArticleFrontiers in pharmacology2021

Comparison of Primary and Secondary Prophylaxis Using PEGylated Recombinant Human Granulocyte-Stimulating Factor as a Cost-Effective Measure in Malignant Neoplasms: A Multicenter Retrospective Study.

Qiuji Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.